» Articles » PMID: 35547105

Correlates of High-dose Antipsychotic Prescription Amongst Outpatients with Schizophrenia in a Nigerian Hospital

Overview
Specialty Psychiatry
Date 2022 May 13
PMID 35547105
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Treatment guidelines recommend the use of antipsychotic monotherapy at effective doses for the treatment of schizophrenia, although about a third of the sufferers still receive high-dose antipsychotic treatment. Current evidence suggests that high-dose antipsychotic prescription (HDAP) not only fails to improve outcomes but also increases side effects.

Aim: Our study aimed to determine the prevalence of HDAP and its association with illness severity, medication adherence behaviour and side effects amongst outpatients with schizophrenia.

Setting: The Federal Neuro-Psychiatric Hospital, Benin-City, Nigeria.

Methods: A cross-sectional study of 320 attendees with schizophrenia at the outpatient department was undertaken. We administered a sociodemographic and antipsychotic medication questionnaire, Mini-International Neuropsychiatric Interview, Positive and Negative Syndrome Scale, Liverpool University Neuroleptic Side Effects Rating Scales and Medication Adherence Rating Scales. High-dose antipsychotic prescription was determined by the ratio of prescribed daily dose to defined daily dose greater than 1.5.

Results: The prevalence of HDAP was 38.4%. Greater severity of illness, experiencing more side effects and poor medication adherence were significantly associated with HDAP.The major predictors of HDAP were antipsychotic polypharmacy and concurrent anticholinergic use.

Conclusion: We conclude that although the use of HDAP amongst patients with schizophrenia remains common, its persistent use should be discouraged.

Citing Articles

Global Neuropsychopharmacological Prescription Trends in Adults with Schizophrenia, Clinical Correlates and Implications for Practice: A Scoping Review.

Ying J, Chew Q, Wang Y, Sim K Brain Sci. 2024; 14(1).

PMID: 38275511 PMC: 10813099. DOI: 10.3390/brainsci14010006.

References
1.
Vinogradov S, Fisher M, Warm H, Holland C, Kirshner M, Pollock B . The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009; 166(9):1055-62. PMC: 3735363. DOI: 10.1176/appi.ajp.2009.09010017. View

2.
Meltzer H, Li Z, Kaneda Y, Ichikawa J . Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(7):1159-72. DOI: 10.1016/j.pnpbp.2003.09.010. View

3.
Danladi J, Falang K, Barde R, Jimam N, Dangiwa D, Jimoh H . Pharmaceutical care and medication adherence in management of psychosis in a Nigerian tertiary hospital. J Res Pharm Pract. 2014; 2(2):83-7. PMC: 4076905. DOI: 10.4103/2279-042X.117388. View

4.
Kay S, Fiszbein A, Opler L . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261-76. DOI: 10.1093/schbul/13.2.261. View

5.
Paton C, Barnes T, Cavanagh M, Taylor D, Lelliott P . High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 2008; 192(6):435-9. DOI: 10.1192/bjp.bp.107.042895. View